サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1551745

プロトンポンプ阻害薬（PPI）の世界市場

Proton Pump Inhibitors (PPIs)
出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 268 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.96円
プロトンポンプ阻害薬（PPI）の世界市場
出版日: 2024年09月10日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 268 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

プロトンポンプ阻害薬（PPI）の世界市場は2030年までに36億米ドルに達する見込み

2023年に29億米ドルと推定されるプロトンポンプ阻害薬（PPI）の世界市場は、2023～2030年の分析期間においてCAGR 3.2%で成長し、2030年には36億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるOver the Counter PPIは、CAGR 3.5%を記録し、分析期間終了時には22億米ドルに達すると予測されます。処方PPIセグメントの成長率は、分析期間中CAGR 2.8%と推定されます。

米国市場は7億9,830万米ドルと推定、中国はCAGR6.2%で成長予測

米国のプロトンポンプ阻害薬（PPI）市場は、2023年に7億9,830万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに7億4,900万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは6.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.0％と2.4％と予測されています。欧州では、ドイツがCAGR 1.7%で成長すると予測されています。

世界のプロトンポンプ阻害薬（PPI）市場- 主要動向と促進要因のまとめ

プロトンポンプ阻害薬（PPI）は酸関連疾患の治療にどのような革命を起こしているか？

プロトンポンプ阻害薬（PPI）は、胃食道逆流症（GERD）、消化性潰瘍、ゾリンジャー・エリソン症候群などの症状緩和と治癒促進を目的とした、胃酸分泌を抑える非常に効果的な手段を提供することで、酸関連疾患の治療に革命を起こしています。PPIは、胃酸分泌に関与する胃粘膜の水素-カリウムATPアーゼ酵素を不可逆的に阻害することによって作用します。このメカニズムにより、制酸薬やH2受容体拮抗薬などの他の治療薬と比較して、より持続的で有意な酸レベルの低下が可能となります。その結果、PPIは、胸やけ、逆流、不快感などの症状を緩和し、慢性的な酸関連症状を管理するための基礎療法となっています。症状のコントロールとびらん性食道炎や消化性潰瘍の治癒の両方におけるPPIの有効性により、PPIは世界中で最もよく処方される医薬品のひとつとなり、何百万人もの患者の生活の質を著しく向上させています。

プロトンポンプ阻害剤の機能を高める技術革新とは？

プロトンポンプ阻害薬（PPI）における技術革新は、新しい製剤、改良されたドラッグデリバリーシステム、併用療法の開発を通じて、プロトンポンプ阻害薬の機能性を高めています。最近の進歩には、24時間にわたってより安定した酸抑制を可能にし、患者のアドヒアランスと転帰を改善する遅延放出型製剤や徐放型製剤の開発が含まれます。さらに、特に錠剤を飲み込むことが困難な患者にとって利便性が高く、吸収が改善される口腔内崩壊錠（ODT）や液状懸濁液などの新しいドラッグデリバリー法も研究されています。もう一つの重要な技術革新は、ヘリコバクター・ピロリ感染によるものを含むより広範な胃腸疾患に対処するために、PPIとプロキネティクスや抗生物質などの他の薬剤を組み合わせた併用療法の開発です。これらの併用療法は治療効果を高め、酸関連疾患の管理により包括的なアプローチを提供します。このような技術革新により、PPIはより汎用性が高く、利用しやすく、効果的なものとなり、より多くの患者さんがPPIの恩恵を受けられるようになっています。

プロトンポンプ阻害薬は長期的な患者の転帰とヘルスケアコストにどのような影響を与えるか？

プロトンポンプ阻害薬（PPI）は、慢性的な酸関連症状を持続的に緩和し、食道狭窄、バレット食道、消化管出血などの合併症を予防することで、長期的な患者の転帰に大きな影響を与えます。症状を効果的に管理し、粘膜の治癒を促進することにより、PPIは患者のQOLを改善し、未治療の酸障害から生じる重篤な合併症のリスクを軽減します。しかし、PPIの長期使用は、栄養吸収不良、骨折リスクの増加、特定の感染症への罹患などの潜在的な副作用に関する懸念を引き起こしています。このような懸念はあるもの、医師の管理下で適切に使用されれば、酸産生を制御し合併症を予防するというPPIの利点は、ほとんどの患者にとってリスクをはるかに上回る。医療費の観点からは、酸関連疾患の合併症に伴う入院やより侵襲的な治療を防ぐことができるため、PPIは一般的に費用対効果が高いです。また、PPIのジェネリック医薬品が普及したことで、PPIはより手頃な価格で入手できるようになり、患者とヘルスケアシステム双方の経済的負担がさらに軽減されています。

プロトンポンプ阻害薬市場の成長を促進する動向は？

プロトンポンプ阻害薬（PPI）市場の成長を牽引しているのは、胃腸疾患の有病率の上昇、酸関連疾患に対する意識の高まり、一般用医薬品（OTC）治療オプションに対する継続的な需要など、いくつかの動向です。ライフスタイルが変化し、食生活がより加工されたものになるにつれて、GERD、消化性潰瘍、消化不良などの疾患の罹患率が増加しており、効果的な酸抑制療法に対する需要が高まっています。さらに、酸関連疾患とその潜在的な合併症に対する意識の高まりが、より多くの個人を治療に向かわせ、PPIの処方薬市場とOTC市場を牽引しています。OTC PPIが入手可能になったことで、これらの薬剤へのアクセスが拡大し、処方箋を必要とせずに症状を管理できるようになった。さらに、PPIの長期的な安全性と有効性に関する継続的な研究により、複雑な疾患や難治性の疾患など、特定の患者集団に対応した、より的を絞った新しい製剤が開発される可能性があります。これらの動向は、現代の消化器病学におけるPPIの重要な役割と、世界の人々の酸関連疾患の管理におけるPPIの継続的な関連性を強調するものです。

調査対象企業の例（全37件）

  • AstraZeneca plc
  • Cadila Pharmaceuticals Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Drugwatch.com, LLC
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Janssen Global Services, LLC
  • Johnson & Johnson Services, Inc.
  • LUPIN Limited
  • Perrigo Company PLC
  • Pfizer Limited
  • RedHill Biopharma Ltd.
  • Sun Pharmaceutical Industries Ltd.;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP24612

Global Proton Pump Inhibitors (PPIs) Market to Reach US$3.6 Billion by 2030

The global market for Proton Pump Inhibitors (PPIs) estimated at US$2.9 Billion in the year 2023, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 3.2% over the analysis period 2023-2030. Over the Counter PPIs, one of the segments analyzed in the report, is expected to record a 3.5% CAGR and reach US$2.2 Billion by the end of the analysis period. Growth in the Prescription PPIs segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$798.3 Million While China is Forecast to Grow at 6.2% CAGR

The Proton Pump Inhibitors (PPIs) market in the U.S. is estimated at US$798.3 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$749.0 Million by the year 2030 trailing a CAGR of 6.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global Proton Pump Inhibitors (PPIs) Market - Key Trends and Drivers Summarized

How Are Proton Pump Inhibitors (PPIs) Revolutionizing the Treatment of Acid-Related Disorders?

Proton Pump Inhibitors (PPIs) are revolutionizing the treatment of acid-related disorders by providing a highly effective means of reducing stomach acid production, thereby alleviating symptoms and promoting healing in conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. PPIs work by irreversibly inhibiting the hydrogen-potassium ATPase enzyme in the stomach lining, which is responsible for acid secretion. This mechanism allows for a more sustained and significant reduction in acid levels compared to other treatments like antacids or H2 receptor antagonists. As a result, PPIs have become the cornerstone therapy for managing chronic acid-related conditions, offering relief from symptoms such as heartburn, regurgitation, and discomfort. The effectiveness of PPIs in both symptom control and the healing of erosive esophagitis and peptic ulcers has made them one of the most commonly prescribed medications worldwide, significantly improving the quality of life for millions of patients.

What Innovations Are Enhancing the Functionality of Proton Pump Inhibitors?

Innovations in proton pump inhibitors (PPIs) are enhancing their functionality through the development of new formulations, improved drug delivery systems, and combination therapies. Recent advancements include the creation of delayed-release and extended-release formulations that allow for more consistent acid suppression over a 24-hour period, improving patient adherence and outcomes. Additionally, researchers are exploring novel drug delivery methods, such as orally disintegrating tablets (ODTs) and liquid suspensions, which offer convenience and improved absorption, particularly for patients who have difficulty swallowing pills. Another significant innovation is the development of combination therapies that pair PPIs with other medications, such as prokinetics or antibiotics, to address a broader range of gastrointestinal conditions, including those caused by Helicobacter pylori infections. These combination therapies enhance the effectiveness of treatment and provide a more comprehensive approach to managing acid-related disorders. These innovations are making PPIs more versatile, accessible, and effective, ensuring that a wider range of patients can benefit from their use.

How Do Proton Pump Inhibitors Impact Long-Term Patient Outcomes and Healthcare Costs?

Proton Pump Inhibitors (PPIs) have a profound impact on long-term patient outcomes by providing sustained relief from chronic acid-related conditions and preventing complications such as esophageal strictures, Barrett's esophagus, and gastrointestinal bleeding. By effectively managing symptoms and promoting mucosal healing, PPIs help patients maintain a better quality of life and reduce the risk of serious complications that can arise from untreated acid disorders. However, the long-term use of PPIs has raised concerns about potential side effects, such as nutrient malabsorption, increased risk of bone fractures, and susceptibility to certain infections. Despite these concerns, when used appropriately under medical supervision, the benefits of PPIs in controlling acid production and preventing complications far outweigh the risks for most patients. From a healthcare cost perspective, PPIs are generally cost-effective due to their ability to prevent hospitalizations and more invasive treatments associated with complications of acid-related disorders. The widespread availability of generic PPI formulations also makes these medications more affordable, further reducing the financial burden on both patients and healthcare systems.

What Trends Are Driving Growth in the Proton Pump Inhibitors Market?

Several trends are driving growth in the Proton Pump Inhibitors (PPIs) market, including the rising prevalence of gastrointestinal disorders, increasing awareness of acid-related conditions, and the continued demand for over-the-counter (OTC) treatment options. As lifestyles change and diets become more processed, there is a growing incidence of conditions like GERD, peptic ulcers, and dyspepsia, leading to greater demand for effective acid suppression therapies. Additionally, increased awareness of acid-related disorders and their potential complications is prompting more individuals to seek medical treatment, driving the prescription and OTC markets for PPIs. The availability of OTC PPIs has expanded access to these medications, allowing individuals to manage symptoms without the need for a prescription, which is particularly appealing to those with mild or occasional symptoms. Furthermore, ongoing research into the long-term safety and efficacy of PPIs is likely to lead to the development of newer, more targeted formulations that cater to specific patient populations, such as those with complex or refractory conditions. These trends underscore the essential role of PPIs in modern gastroenterology and their continued relevance in managing acid-related disorders in the global population.

Select Competitors (Total 37 Featured) -

  • AstraZeneca plc
  • Cadila Pharmaceuticals Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Drugwatch.com, LLC
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Janssen Global Services, LLC
  • Johnson & Johnson Services, Inc.
  • LUPIN Limited
  • Perrigo Company PLC
  • Pfizer Limited
  • RedHill Biopharma Ltd.
  • Sun Pharmaceutical Industries Ltd.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Proton Pump Inhibitors (PPIs) - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Gastrointestinal Disorders Driving Demand for PPIs
    • Growing Awareness of Acid Reflux and GERD Management Options
    • Rising Geriatric Population and Associated Gastrointestinal Conditions
    • Concerns Over Long-Term PPI Use and Potential Side Effects Influencing Prescribing Practices
    • Generic Drug Market Expansion Following PPI Patent Expirations
    • E-commerce and Online Pharmacies Expanding PPI Availability
    • Challenges in Over-the-Counter PPI Sales and Self-Medication Risks
    • Impact of Digital Health Technologies on Patient Management and Monitoring
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Proton Pump Inhibitors (PPIs) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Proton Pump Inhibitors (PPIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Over the Counter PPIs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Over the Counter PPIs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Over the Counter PPIs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Prescription PPIs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Prescription PPIs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Prescription PPIs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Injectable Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • JAPAN
    • Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • CHINA
    • Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: China 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • EUROPE
    • Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Proton Pump Inhibitors (PPIs) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • FRANCE
    • Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: France 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • GERMANY
    • Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Spain 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Russia 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Proton Pump Inhibitors (PPIs) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Australia 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • INDIA
    • Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: India Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: India 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: India 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: South Korea 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for Proton Pump Inhibitors (PPIs) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Latin America 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Argentina 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Brazil 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Mexico 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Rest of Latin America 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for Proton Pump Inhibitors (PPIs) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Middle East 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Iran 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Israel 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Saudi Arabia 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: UAE 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Middle East 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • AFRICA
    • Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Africa 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030

IV. COMPETITION